血清BDNF和认知正常的老年人中MCI的进展:一个前性队列研究
Kyungtae Kim1, Min Soo Byun2, Dahyun Yi3
1Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
The journal of prevention of Alzheimer's disease
|May 25, 2025
概括
高血清脑衍生神经营养因子 (BDNF) 水平与老年人患轻度认知障碍 (MCI) 的风险降低有关. 这种保护作用在妇女和特定子组中尤为明显.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 生物化学 生物化学
背景情况:
- 大脑衍生神经营养因子 (BDNF) 对神经元健康至关重要,并与阿尔茨海默病病理生理学有关.
- 以前的人类研究表明,血液BDNF升高和痴呆风险降低之间存在相关性.
- 血清BDNF水平与从认知正常 (CN) 过渡到轻度认知障碍 (MCI) 之间的特定关联需要进一步调查.
研究的目的:
- 调查CN老年人血清BDNF水平较高是否会在4年内预测MCI发病率较低.
- 确定可能会缓解BDNF和MCI进展之间的关系的潜在人口或临床因素.
主要方法:
- 进行了一项前性队列研究,涉及274名认知正常的老年人 (年龄为55-90岁).
- 纵向数据分析追踪了4年的随访期内MCI的进展.
- 统计模型,包括生存分析,用于评估基线血清BDNF水平与MCI发病率之间的关联,控制各种混因素.
主要成果:
- 血清BDNF水平较高的个体与水平较低的个体相比,MCI发病率明显较低 (HR,0.27;P = 0.006).
- 在调整了许多共同变量之后,这种保护性关联仍然很重要,包括遗传因素,生物标志物和生活方式因素 (HR,0.14;P < 0.001).
- 亚组分析表明,BDNF的保护作用在女性,75岁以下的个人,没有大学教育的人和粉样蛋白PET阴性参与者中更为明显.
结论:
- 在认知健康的老年人中,血清BDNF水平升高似乎会对MCI的进展产生保护作用.
- 这些发现突出了BDNF作为潜在的生物标志物认知能力下降风险.
- 观察到的性别,年龄,教育和粉样蛋白状况的缓解效应表明了个性化的神经保护方法.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.6K
相关概念视频
Cognitive Development During Adulthood
317
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
317
Alzheimer's Disease: Overview
689
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
689
